Benjamin Djulbegović

Economics, Econometrics and FinanceDecision SciencesMathematicsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 18 papers. Top paper: “Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval”.

Larger effect sizes in nonrandomized studies are associated with higher rates of EMA licensing approval

Journal of Clinical Epidemiology(2018)10.1016/j.jclinepi.2018.01.011

N/A

2.0DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, Tea Reljic, Magali VanDenBergh, Rahul Mhaskar +4 more

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials

JAMA Network Open(2019)10.1001/jamanetworkopen.2019.11111

N/A

1.5DataRank · unranked

42 citations

Paul Glasziou, Farina A. Klocksieben, John P. A. Ioannidis, Iain Chalmers, Farina Klocksieben +2 more

Optimal type I and type II error pairs when the available sample size is fixed

Journal of Clinical Epidemiology(2013)10.1016/j.jclinepi.2013.03.002

N/A

0.524DataRank · unranked

32 citations

Iztok Hozo, John P. A. Ioannidis, Benjamin Djulbegović

Modern health care as a game theory problem

European Journal of Clinical Investigation(2014)10.1111/eci.12380

N/A

0.494DataRank · unranked

26 citations

Iztok Hozo, Benjamin Djulbegović, John P. A. Ioannidis

Improving the Drug Development Process

JAMA(2014)10.1001/jama.2013.283742

N/A

0.489DataRank · unranked

25 citations

Iztok Hozo, John P. A. Ioannidis, Benjamin Djulbegović

Precision medicine for individual patients should use population group averages and larger, not smaller, groups

European Journal of Clinical Investigation(2018)10.1111/eci.13031

N/A

0.416DataRank · unranked

15 citations

John P. A. Ioannidis, Benjamin Djulbegović

Identification of threshold for large (dramatic) effects that would obviate randomized trials is not possible

Journal of Clinical Epidemiology(2022)10.1016/j.jclinepi.2022.01.016

N/A

0.360DataRank · unranked

10 citations

Benjamin Djulbegović, Austin J. Parish, John P. A. Ioannidis, Iztok Hozo

Federal Funding and Citation Metrics of US Biomedical Researchers, 1996 to 2022

JAMA Network Open(2022)10.1001/jamanetworkopen.2022.45590

N/A

0.330DataRank · unranked

8 citations

Iztok Hozo, Benjamin Djulbegović, John P. A. Ioannidis

Methods proposed for monitoring the implementation of evidence-based research: a cross-sectional study

Journal of Clinical Epidemiology(2024)10.1016/j.jclinepi.2024.111247

N/A

0.290DataRank · unranked

5 citations

Małgorzata M. Bala, Joanna Zając, Tomislav Meštrović, Sandra Buttigieg, Mary Yanakoulia +39 more

There is no upper limit on the maximum effect that can be detected in randomized trials

Journal of Clinical Epidemiology(2025)10.1016/j.jclinepi.2025.111828

N/A

0.223DataRank · unranked

3 citations

Iztok Hozo, Renata Iskander, Austin J. Parish, Jonathan Kimmelman, Benjamin Djulbegović +1 more

Modern health care as a game theory problem: reply

European Journal of Clinical Investigation(2015)10.1111/eci.12414

N/A

0.208DataRank · unranked

3 citations

Iztok Hozo, Benjamin Djulbegović, John P. A. Ioannidis

Theory of clinical therapeutic progress: reconciling equipoise with fat-tailed (skewed) outcomes

Journal of Clinical Epidemiology(2025)10.1016/j.jclinepi.2025.112004

N/A

0DataRank · unranked

0 citations

Benjamin Djulbegović, Iztok Hozo

Progress in Cancer Therapeutics: Is There an Upper Limit on the Maximum Effect that Can Be Detected in Randomized Trials

SSRN Electronic Journal(2025)10.2139/ssrn.5159364

N/A

0DataRank · unranked

0 citations

Iztok Hozo, Renata Iskander, Austin J. Parish, Jonathan Kimmelman, John P. A. Ioannidis +2 more

Study Design and the Drug Development Process—Reply

JAMA(2014)10.1001/jama.2014.3829

N/A

0DataRank · unranked

0 citations

Iztok Hozo, Benjamin Djulbegović, John P. A. Ioannidis

GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making

Journal of Clinical Epidemiology(2020)10.1016/j.jclinepi.2020.09.018

N/A

0DataRank · unranked

308 citations

Carlos Canelo‐Aybar, Elie A. Akl, James M. Bowen, John R. Bucher, Weihsueh A. Chiu +39 more

Using Twitter for the identification of COVID-19 vaccine-associated haematological adverse events

The Lancet Haematology(2021)10.1016/s2352-3026(21)00378-1

N/A

0DataRank · unranked

12 citations

Krishna Gundabolu, Larry W. Kwak, Benjamin Djulbegović, Oscar Champigneulle, Brian D. Josephson +3 more

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

The Oncologist(2021)10.1002/onco.13713

N/A

0DataRank · unranked

2 citations

Sumimasa Nagai, Andrew C. Bennett, Shamia Hoque, Chadi Nabhan, Martin W. Schoen +18 more

Federal Funding and Citation Metrics of Biomedical Research in the USA

medRxiv(2022)10.1101/2022.08.31.22279467

N/A

0DataRank · unranked

0 citations

Iztok Hozo, Benjamin Djulbegović, John P. A. Ioannidis